These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15621782)

  • 1. Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.
    Kim DH; Lee NY; Kim JG; Sohn SK; Won DI; Suh JS; Lee GS; Chae SC; Lee KB
    Leuk Lymphoma; 2005 Jan; 46(1):63-70. PubMed ID: 15621782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment outcome of multidrug resistance related mRNA expression and c-jun-N-terminal kinase activity in patients with acute myeloid leukemia].
    Do JH; Oh SH; Song EJ; Chung JS; Kang CD; Lee EY
    Korean J Lab Med; 2007 Aug; 27(4):229-36. PubMed ID: 18094581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
    Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
    Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
    Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
    Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
    Illmer T; Schaich M; Oelschlägel U; Nowak R; Renner U; Ziegs B; Subat S; Neubauer A; Ehninger G
    Leuk Res; 1999 Jul; 23(7):653-63. PubMed ID: 10400187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
    Ho MM; Hogge DE; Ling V
    Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
    Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
    Leuk Res; 2003 Feb; 27(2):183-91. PubMed ID: 12526924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
    Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
    Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
    van der Holt B; Löwenberg B; Burnett AK; Knauf WU; Shepherd J; Piccaluga PP; Ossenkoppele GJ; Verhoef GE; Ferrant A; Crump M; Selleslag D; Theobald M; Fey MF; Vellenga E; Dugan M; Sonneveld P
    Blood; 2005 Oct; 106(8):2646-54. PubMed ID: 15994288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.
    Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
    Adv Exp Med Biol; 1999; 457():161-75. PubMed ID: 10500791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
    van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
    Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.
    da Silveira Júnior LS; Soares VL; Jardim da Silva AS; Gil EA; Pereira de Araújo MDG; Merces Gonçalves CA; Paiva AS; Moura de Oliveira TM; Oliveira GHM; Kramer Cavacanti E Silva DG; de Araújo Moura Lemos TM; Moretti Rebecchi IM; de Farias Sales VS; Luchessi AD; Cavalcanti Júnior GB
    Int J Lab Hematol; 2020 Oct; 42(5):594-603. PubMed ID: 32452631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival.
    Borg AG; Burgess R; Green LM; Scheper RJ; Yin JA
    Br J Haematol; 1998 Dec; 103(4):1083-91. PubMed ID: 9886324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia.
    Sincock PM; Ashman LK
    Leukemia; 1997 Nov; 11(11):1850-7. PubMed ID: 9369417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes.
    Kim DH; Lee NY; Sung WJ; Baek JH; Kim JG; Sohn SK; Suh JS; Lee KS; Lee KB
    Acta Haematol; 2005; 114(2):78-83. PubMed ID: 16103629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
    Choi CH; Ling V
    Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
    Köhler T; Leiblein S; Borchert S; Eller J; Rost AK; Lassner D; Krahl R; Helbig W; Wagner O; Remke H
    Adv Exp Med Biol; 1999; 457():177-85. PubMed ID: 10500792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).
    Samdani A; Vijapurkar U; Grimm MA; Spier CS; Grogan TM; Glinsmann-Gibson BJ; List AF
    Leuk Res; 1996 Feb; 20(2):175-80. PubMed ID: 8628017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.